title: Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer.
abstract: OBJECTIVE
  This prospective study aimed to estimate the prevalence and course of depression during chemotherapy in women with Stage I-III breast cancer, identify potential risk factors for depression and determine which treatments for depression were being used and which were most preferred.
  
  
  METHODS
  Thirty-two women were followed over consecutive chemotherapy infusions, with 289 assessments conducted altogether (mean, 9.0 assessments/subject). Current depression, anxiety, physical symptoms and mental health service use were recorded during each assessment. A linear mixed effects model was used to identify factors associated with depression. Patients also ranked depression treatment preferences. We referred patients with more severe depression for treatment.
  
  
  RESULTS
  Clinically significant depression was identified in 37.5% of patients. Depression severity tended to peak at 12-14 weeks and 32 or more weeks of chemotherapy. Depression severity was associated with anxiety severity, physical symptom burden, non-White race, receiving one's first chemotherapy regimen, Adriamycin-Cytoxan chemotherapy and chemotherapy duration. Most (65.5%) patients preferred evidence-based treatments for depression, and 66.7% of depressed patients were using such treatments.
  
  
  CONCLUSIONS
  Depression is common in women receiving chemotherapy for breast cancer. Most patients prefer evidence-based depression treatments. We recommend regular screening for depression during chemotherapy to ensure adequate detection and patient-centered treatment.
authors: University of Washington, Seattle, WA 98195, USA.
authors: Julia C
authors: JC
authors: Reece
authors: Ya-Fen
authors: YF
authors: Chan
authors: Julia
authors: J
authors: Herbert
authors: Julie
authors: J
authors: Gralow
authors: Jesse R
authors: JR
authors: Fann
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000150:complications / Q000523:psychology; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D015331:Cohort Studies; D003866:Depressive Disorder / Q000150:complications / Q000523:psychology* / Q000628:therapy; D018450:Disease Progression; D005221:Fatigue / Q000150:complications / Q000523:psychology; D005260:Female; D006801:Humans; D008605:Mental Health Services / Q000706:statistics & numerical data; D008875:Middle Aged; D057240:Patient Preference; D011446:Prospective Studies; D011613:Psychotherapy; D012720:Severity of Illness Index
chemical_list: D000928:Antidepressive Agents; D000970:Antineoplastic Agents